Summary
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous self-administration. Benzhydrocodone HCl (KP201) is a prodrug of hydrocodone with limited bioavailability when taken intranasally or intravenously, or taken orally at supratherapeutic doses. This study assessed the abuse liability, relative bioavailability, and safety of KP201/APAP, compared with that of HB/APAP (Norco®), when administered at supratherapeutic oral doses to non-dependent, recreational opioid users. Both KP201/APAP and HB/APAP were generally well tolerated and had similar Drug Liking scores, but KP201/APAP displayed lower peak and cumulative systemic exposure to hydrocodone at high and mid oral doses.
Register to download
Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
You may also be interested in:
Newsletter
Industry Watch
With fall in the air in the northern hemisphere, it’s also a week full of noteworthy news in clinical development. New research shines a light on…
Poster
A Blueprint to Success: Onboarding a Medical Writer
Onboarding is the process of welcoming new employees into an organization and providing them with the tools, resources, and knowledge to become…
Case Study
Collaboration in Neonatal Study Addresses and Resolves Multi-Stage Difficulties
PRA’s project team turned around a challenging neonatal seizure study to enable successful recruitment. The relationships between the sponsor and the…